397 related articles for article (PubMed ID: 18488413)
21. Liposomes in Active, Passive and Acoustically-Triggered Drug Delivery.
Basha SA; Salkho N; Dalibalta S; Husseini GA
Mini Rev Med Chem; 2019; 19(12):961-969. PubMed ID: 30961495
[TBL] [Abstract][Full Text] [Related]
22. Challenges in development of targeted liposomal therapeutics.
Sawant RR; Torchilin VP
AAPS J; 2012 Jun; 14(2):303-15. PubMed ID: 22415612
[TBL] [Abstract][Full Text] [Related]
23. Future directions of liposome- and immunoliposome-based cancer therapeutics.
Park JW; Benz CC; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
[TBL] [Abstract][Full Text] [Related]
24. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
Maruyama K
Adv Drug Deliv Rev; 2011 Mar; 63(3):161-9. PubMed ID: 20869415
[TBL] [Abstract][Full Text] [Related]
25. Liposomal delivery systems for anti-cancer analogues of vitamin E.
Koudelka S; Turanek Knotigova P; Masek J; Prochazka L; Lukac R; Miller AD; Neuzil J; Turanek J
J Control Release; 2015 Jun; 207():59-69. PubMed ID: 25861728
[TBL] [Abstract][Full Text] [Related]
26. Liposomal cancer therapy: exploiting tumor characteristics.
Kaasgaard T; Andresen TL
Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
[TBL] [Abstract][Full Text] [Related]
27. Development of liposomal anticancer drugs.
Hyodo K; Yamamoto E; Suzuki T; Kikuchi H; Asano M; Ishihara H
Biol Pharm Bull; 2013; 36(5):703-7. PubMed ID: 23649329
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
29. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
30. Liposome-based drug delivery of various anticancer agents of synthetic and natural product origin: a patent overview.
Akhtar N; Mohammed SA; Singh V; Abdellatif AA; Mohammad HA; Ahad A; Yusuf M; Khadri H; Naz M; Khan O; Rashid M; Khan RA
Pharm Pat Anal; 2020 May; 9(3):87-116. PubMed ID: 32609057
[TBL] [Abstract][Full Text] [Related]
31. Surface-active liposomes for targeted cancer therapy.
Sofou S
Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032
[TBL] [Abstract][Full Text] [Related]
32. Targeting anticancer drugs to tumor vasculature using cationic liposomes.
Abu Lila AS; Ishida T; Kiwada H
Pharm Res; 2010 Jul; 27(7):1171-83. PubMed ID: 20333455
[TBL] [Abstract][Full Text] [Related]
33. Robust Microfluidic Technology and New Lipid Composition for Fabrication of Curcumin-Loaded Liposomes: Effect on the Anticancer Activity and Safety of Cisplatin.
Hamano N; Böttger R; Lee SE; Yang Y; Kulkarni JA; Ip S; Cullis PR; Li SD
Mol Pharm; 2019 Sep; 16(9):3957-3967. PubMed ID: 31381352
[TBL] [Abstract][Full Text] [Related]
34. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
Gilabert-Oriol R; Ryan GM; Leung AWY; Firmino NS; Bennewith KL; Bally MB
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261606
[TBL] [Abstract][Full Text] [Related]
35. Magnetic cationic liposomal nanocarriers for the efficient drug delivery of a curcumin-based vanadium complex with anticancer potential.
Halevas E; Mavroidi B; Swanson CH; Smith GC; Moschona A; Hadjispyrou S; Salifoglou A; Pantazaki AA; Pelecanou M; Litsardakis G
J Inorg Biochem; 2019 Oct; 199():110778. PubMed ID: 31442839
[TBL] [Abstract][Full Text] [Related]
36. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
[TBL] [Abstract][Full Text] [Related]
37. Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J; Metselaar JM; Storm G; van der Pluijm G
Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
[TBL] [Abstract][Full Text] [Related]
38. Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.
Modi S; Xiang TX; Anderson BD
J Control Release; 2012 Sep; 162(2):330-9. PubMed ID: 22800581
[TBL] [Abstract][Full Text] [Related]
39. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
40. Functional liposomes in the cancer-targeted drug delivery.
Tila D; Ghasemi S; Yazdani-Arazi SN; Ghanbarzadeh S
J Biomater Appl; 2015 Jul; 30(1):3-16. PubMed ID: 25823898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
